Cangene wins US FDA nod for botulism antitoxin
This article was originally published in Scrip
Executive Summary
Canadian biopharma Cangene won the US FDA's nod on 22 March to market the firm's botulism antitoxin (Equine), heptavalent (A, B, C, D, E, F, G) to treat patients with symptomatic botulism following suspected or documented exposure to botulinum neurotoxin.